Janux Therapeutics and Merck & Co. (NYSE:MRK) have entered a license and strategic collaboration agreement to discover, develop as well as commercialize next-gen T cell engager immunotherapies for cancer treatment. Merck to pay Janux $550.5 upfront payment following a collaboration agreement The collaboration aims to leverage Janux’s Novel Tumor Activated […]